First closing of Series B financing round
Multiple ascending dose study with AON-D21 completed
Single ascending dose study with AON-D21 completed
First healthy volunteer dosed with AON-D21
German Medicines Agency BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte) approved the First-in-Human study with AON-D21
Germany’s Education Minister announced to significantly fund the further development of AON-D21 by the Federal Ministry of Education and Research under the Covid initiative ’Research and development of urgently needed therapeutics against SARS-CoV-2’ (‘Forschung und Entwicklung dringend benötigter Therapeutika gegen SARS-CoV-2’), grant number: 16LW0006.
Series A2 1st Closing successfully completed by registration of the capital increase in the commercial register
Publication of key data shedding light on the efficacy of AON-D21 in pneumococcal pneumonia in the scientific Journal Anesthesiology (Vol. 132, 795-807, 2020)